Assessment
Questionnaire

Have a symptom?
See what questions
a doctor would ask.
 
News » New drug provides hope for mesothelioma sufferers
 

New drug provides hope for mesothelioma sufferers

The general survival rate for people diagnosed with asbestos-induced mesothelioma is one year. A new drug called pemetrexed has been approved by the Therapeutic Goods Administration. The drug relieves breathing difficulties and pain as well as improving survival rates. Some have survived for up to two years.

Source: summary of medical news story as reported by Herald Sun

Related Disease Topics:

Article Source Details

About: New drug provides hope for mesothelioma sufferers

Date: 20 October 2004

Source: Herald Sun

URL: http://www.heraldsun.news.com.au/common/story_page/0,5478,11123561%5E2862,00.html

Related Medical Topics

This summary article refers to the following medical categories:

  • Asbestosis
  • Medication and asbestosis
  • Medication and mesothelioma
  • Medication and cancer

More News Topics

  • Mother survives pregnancy with leukemia
  • Mother wrongly told her newborn was suffering from brain damage
  • Mother's chances of survival at 7 percent due to delayed diagnosis of cancer
  • Mother's diagnosis of meningitis
  • Mother’s diet affects children’s leukemia risk
  • MRI dangers with carelessness
  • MRSA caused coma in woman
  • MS cause coming to light
  • Multi-resistant bacteria found in hospital patients
  • Multiple sclerosis inhibited in those with greater exposure to younger siblings
  •  

    By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

    Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise